266 related articles for article (PubMed ID: 9152109)
1. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis.
Mohr DC; Goodkin DE; Likosky W; Gatto N; Baumann KA; Rudick RA
Arch Neurol; 1997 May; 54(5):531-3. PubMed ID: 9152109
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment.
Mohr DC; Goodkin DE; Likosky W; Gatto N; Neilley LK; Griffin C; Stiebling B
Mult Scler; 1996 Dec; 2(5):222-6. PubMed ID: 9050360
[TBL] [Abstract][Full Text] [Related]
3. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis.
Schwartz CE; Coulthard-Morris L; Cole B; Vollmer T
Arch Neurol; 1997 Dec; 54(12):1475-80. PubMed ID: 9400356
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune hyperthyroidism in patients with multiple sclerosis treated with interferon beta-1b.
Schwid SR; Goodman AD; Mattson DH
Arch Neurol; 1997 Sep; 54(9):1169-90. PubMed ID: 9311363
[TBL] [Abstract][Full Text] [Related]
5. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
Drulovic J; Cukic M; Grgic S; Dincic E; Raicevic R; Nadj C; Toncev G; Vojinovic S; Mesaros S; Kisic Tepavcevic D; Dujmovic I; Tadic D; Miletic-Drakulic S; Dackovic J; Kostic S; Erakovic J; Sakalas L; Savic D; Suknjaja V; Martinovic V; Maric G; Pekmezovic T
Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
[TBL] [Abstract][Full Text] [Related]
6. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
[TBL] [Abstract][Full Text] [Related]
7. Use of interferon beta 1b for multiple sclerosis. Patients will put up with side effects because of their desire to beat the disease.
Chellingsworth M
BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939140
[No Abstract] [Full Text] [Related]
8. Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
Zettl UK; Bauer-Steinhusen U; Glaser T; Hechenbichler K; Limmroth V;
BMC Neurol; 2013 Sep; 13():117. PubMed ID: 24011220
[TBL] [Abstract][Full Text] [Related]
9. Use of interferon beta 1b for multiple sclerosis. Manufacturer defends the drug.
Longthorne PN
BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939141
[No Abstract] [Full Text] [Related]
10. Use of interferon beta 1b for multiple sclerosis. Importance of relapses must not be underestimated.
Cardy P
BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939142
[No Abstract] [Full Text] [Related]
11. Treatment of multiple sclerosis with interferon beta-1 b.
Abdul-Ahad A; Shah S; Galazka A
Neurology; 1997 Aug; 49(2):641-2. PubMed ID: 9270626
[No Abstract] [Full Text] [Related]
12. Factors leading patients to discontinue multiple sclerosis therapies.
Daugherty KK; Butler JS; Mattingly M; Ryan M
J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
Petkau J; White R
Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
[No Abstract] [Full Text] [Related]
14. Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.
Blake G; Murphy S
Neurology; 1997 Dec; 49(6):1747-8. PubMed ID: 9409387
[No Abstract] [Full Text] [Related]
15. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
[TBL] [Abstract][Full Text] [Related]
16. Interferon beta in multiple sclerosis.
Richards RG
BMJ; 1996 Nov; 313(7066):1159. PubMed ID: 8916730
[No Abstract] [Full Text] [Related]
17. Why interferon beta 1b was licensed is a mystery.
Harvey P
BMJ; 1996 Aug; 313(7052):297-8. PubMed ID: 8704553
[No Abstract] [Full Text] [Related]
18. Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis.
Ossege LM; Sindern E; Patzold T; Malin JP
Int Immunopharmacol; 2001 Jun; 1(6):1085-100. PubMed ID: 11407304
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
[TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
